A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.

Autor: Sanchez-Felipe L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Vercruysse T; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium., Sharma S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Ma J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Lemmens V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Van Looveren D; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium., Arkalagud Javarappa MP; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Boudewijns R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Malengier-Devlies B; KU Leuven Department of Microbiology, Immunology and Transplantation,Rega Institute, Immunity and Inflammation Research Group, Immunobiology Unit, KU Leuven, Leuven, Belgium., Liesenborghs L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Kaptein SJF; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., De Keyzer C; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Bervoets L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Debaveye S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Rasulova M; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium., Seldeslachts L; KU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, KU Leuven, Leuven, Belgium., Li LH; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Jansen S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Yakass MB; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA.; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana., Verstrepen BE; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Böszörményi KP; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Kiemenyi-Kayere G; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., van Driel N; Animal Science Department, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Quaye O; Global Virus Network (GVN), Baltimore, MD, USA.; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana., Zhang X; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Ter Horst S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Mishra N; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA.; Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, India., Deboutte W; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratorium Klinische en Epidemiologische Virologie, KU Leuven, Leuven, Belgium., Matthijnssens J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratorium Klinische en Epidemiologische Virologie, KU Leuven, Leuven, Belgium., Coelmont L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, MD, USA., Vandermeulen C; Leuven University Vaccinology Center (LUVAC), KU Leuven, Leuven, Belgium.; KU Leuven Department of Public Health and Primary Care, KU Keuven, Leuven, Belgium., Heylen E; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Vergote V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Schols D; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Wang Z; Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA., Bogers W; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Kuiken T; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands., Verschoor E; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Cawthorne C; KU Leuven Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium., Van Laere K; KU Leuven Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium., Opdenakker G; KU Leuven Department of Microbiology, Immunology and Transplantation,Rega Institute, Immunity and Inflammation Research Group, Immunobiology Unit, KU Leuven, Leuven, Belgium., Vande Velde G; KU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, KU Leuven, Leuven, Belgium., Weynand B; KU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium., Teuwen DE; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Matthys P; KU Leuven Department of Microbiology, Immunology and Transplantation,Rega Institute, Immunity and Inflammation Research Group, Immunobiology Unit, KU Leuven, Leuven, Belgium., Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium. johan.neyts@kuleuven.be.; Global Virus Network (GVN), Baltimore, MD, USA. johan.neyts@kuleuven.be., Jan Thibaut H; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium. hendrikjan.thibaut@kuleuven.be.; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium. hendrikjan.thibaut@kuleuven.be., Dallmeier K; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium. kai.dallmeier@kuleuven.be.; Global Virus Network (GVN), Baltimore, MD, USA. kai.dallmeier@kuleuven.be.
Jazyk: angličtina
Zdroj: Nature [Nature] 2021 Feb; Vol. 590 (7845), pp. 320-325. Date of Electronic Publication: 2020 Dec 01.
DOI: 10.1038/s41586-020-3035-9
Abstrakt: The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response 1 . Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and-concomitantly-protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model 2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
Databáze: MEDLINE
Externí odkaz: